Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Finished Goods (2021 - 2025)

Universe Pharmaceuticals' Finished Goods history spans 5 years, with the latest figure at $1.6 billion for Q3 2025.

  • On a quarterly basis, Finished Goods rose 40.91% to $1.6 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $1.6 billion, a 40.91% increase, with the full-year FY2025 number at $1.6 billion, up 40.91% from a year prior.
  • Finished Goods hit $1.6 billion in Q3 2025 for Universe Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Over the last five years, Finished Goods for UPC hit a ceiling of $1.6 billion in Q3 2025 and a floor of $1.3 million in Q3 2022.
  • Historically, Finished Goods has averaged $551.2 million across 5 years, with a median of $2.8 million in 2023.
  • Biggest five-year swings in Finished Goods: crashed 32.14% in 2022 and later surged 40997.28% in 2024.
  • Tracing UPC's Finished Goods over 5 years: stood at $2.0 million in 2021, then tumbled by 32.14% to $1.3 million in 2022, then skyrocketed by 107.64% to $2.8 million in 2023, then surged by 40997.28% to $1.1 billion in 2024, then surged by 40.91% to $1.6 billion in 2025.
  • Business Quant data shows Finished Goods for UPC at $1.6 billion in Q3 2025, $1.1 billion in Q3 2024, and $2.8 million in Q3 2023.